Silence Therapeutics Plc American Depository Share (SLN) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Silence Therapeutics Plc American Depository Share (SLN) has outperformed Verastem (VSTM) over the past year, gaining 81.3% versus a loss of 9.3%. Over five years, SLN leads with a -56.4% price change compared with -75.5% for VSTM. Verastem is the larger company by market cap ($754.8 million vs $616.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SLN | VSTM |
|---|---|---|
| Share price | $9.93 | $8.34 |
| Market cap | $616.88M | $754.85M |
| 1-day change | +4.25% | +2.77% |
| YTD return | +56.58% | +5.05% |
| 1-year return | +81.33% | -9.28% |
| 5-year return | -56.37% | -75.51% |
| EPS (TTM) | $-1.29 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.58 | $10.82 |
| 52-week low | $4.19 | $3.43 |
| Distance from 52-week high | -43.53% | -22.97% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +232.49% | +79.96% |
| Average volume | 1.14M | 2.25M |
| Shares outstanding | 62.15M | 90.56M |
| Employees | 88 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLN has outperformed VSTM by 90.6 percentage points over the past year.
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
SLN vs VSTM FAQ
Which is bigger, Silence Therapeutics Plc American Depository Share or Verastem?
Verastem (VSTM) is larger, with a market capitalization of $754.85M compared with $616.88M for Silence Therapeutics Plc American Depository Share (SLN).
Which stock has performed better over the past year, SLN or VSTM?
SLN returned +81.33% over the past 12 months, compared with -9.28% for VSTM (price return, excluding dividends). Past performance does not predict future results.
Are Silence Therapeutics Plc American Depository Share and Verastem in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.